Enveric Biosciences advances drug development for mental health indications
Advancing to IND-enabling studies with multiple drug candidates
Advancing to IND-enabling studies with multiple drug candidates
The facility is among 12 centres established worldwide, and the first in Asia
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
The goal for the project is the identification and optimization of anti-viral compounds.
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Subscribe To Our Newsletter & Stay Updated